Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

Cited by (1,003)

Items 201–300 of 1,003

1. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair
   Toky Ratovomanana, Romain Cohen, Magali Svrcek, Florence Renaud, Pascale Cervera, Aurélie Siret, Quentin Letourneur, Olivier Buhard, Pierre Bourgoin, Erell Guillerm et al. · 2021 · Gastroenterology
2. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer
   Sakti Chakrabarti, Leslie A. Bucheit, Jason Scott Starr, Racquel D. Innis-Shelton, Ardaman P. Shergill, Hiba I. Dada, Regina Resta, Stephanie Ann Wagner, Naomi H. Fei, Pashtoon Murtaza Kasi · 2022 · Journal for ImmunoTherapy of Cancer
3. Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing
   Kai Chen, Qi Wang, Xinxin Liu, Xiaodong Tian, Aimei Dong, Yinmo Yang · 2023 · Journal of Translational Medicine
4. Baseline and early changes in the neutrophil–lymphocyte ratio (NLR) predict survival outcomes in advanced colorectal cancer patients treated with immunotherapy
   Hui Ouyang, Bijing Xiao, Yan Huang, Zhi‐Qiang Wang · 2023 · International Immunopharmacology
5. Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies
   D.Y. Luo, Jing Zhou, Shuiliang Ruan, Binzhong Zhang, Huali Zhu, Yangming Que, Shijie Ying, Xiaowen Li, Yuanmin Hu, Zhengwei Song · 2025 · Cell Death and Disease
6. Integrative proteogenomic characterization of early esophageal cancer
   Li, Lingling, Jiang, Dongxian, Zhang, Qiao, Liu, Hui, Xu, Fujiang, Guo, Chunmei, Qin, Zhaoyu, Wang, Haixing, Feng, Jinwen, Liu, Yang et al. · 2023 · Nature Communications
7. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
   Vito Amodio, Gianluca Mauri, Nicole Megan Reilly, Andrea Sartore Bianchi, Salvatore Siena, Alberto Bardelli, Giovanni Germano · 2021 · Cancers
8. Radiomics: A review of current applications and possibilities in the assessment of tumor microenvironment
   Caiqiang Xue, Qing Zhou, Huaze Xi, Junlin Zhou · 2022 · Diagnostic and Interventional Imaging
9. Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer
   Zhaohui Jin, Frank A. Sinicrope · 2021 · Cancers
10. ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma
    Katrina Sophia Pedersen, Nathan R. Foster, Michael James Overman, Patrick McKay Boland, Sunnie S. Kim, Kathryn A. Arrambide, Brandy L. Jaszewski, Tanios Bekaii‐Saab, Rondell Patrell Graham, Jack Welch et al. · 2021 · Clinical Cancer Research
11. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
    Alexander Stein, Donjetë Simnica, Christoph Schultheiß, Rebekka Scholz, Joseph Tintelnot, Eray Goekkurt, Lisa von Wenserski, Edith Willscher, Lisa Paschold, Markus Sauer et al. · 2021 · Journal for ImmunoTherapy of Cancer
12. Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers
    Lindsey Carlsen, Kelsey E. Huntington, Wafik S. El‐Deiry · 2022 · Cancers
13. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control
    Kyle Concannon, Benjamin B. Morris, Carl Michael Gay, Lauren A. Byers · 2023 · Molecular Cell
14. Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies
    Randrian, Violaine, Evrard, Camille, Tougeron, David · 2021 · Cancers
15. Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)
    Pauline Gilson, Jean‐Louis Merlin, Alexandre Harlé · 2021 · Cancers
16. Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer
    Shun Li, Ruisi Na, Xuehan Li, Yanqiao Zhang, Tongsen Zheng · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
17. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors
    Paolo Manca, Francesca Corti, Rossana Intini, Giacomo Mazzoli, Rosalba Miceli, Marco Maria Germani, Francesca Bergamo, Margherita Ambrosini, Eleonora Cristarella, Riccardo Cerantola et al. · 2023 · European Journal of Cancer
18. Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors
    Yoshiaki Nakamura, Hiroshi Ozaki, Makoto Ueno, Yoshito Komatsu, Satoshi Yuki, Taito Esaki, Hiroya Taniguchi, Yu Sunakawa, Kensei Yamaguchi, Ken Kato et al. · 2024 · Nature Medicine
19. Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
    Keigo Chida, Akihito Kawazoe, Toshihiro Suzuki, Masahito Kawazu, Toshihide Ueno, Kazumasa Takenouchi, Yoshiaki Nakamura, Yasutoshi Kuboki, Daisuke Kotani, Takashi Kojima et al. · 2022 · Clinical Cancer Research
20. Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy
    Chiara Cremolini, Emanuela Vitale, Raffaella Rastaldo, Claudia Giachino · 2021 · Nanomaterials
21. Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
    Selina K. Wong, Caroline A. Nebhan, Douglas Buckner Johnson · 2021 · Frontiers in Immunology
22. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022
    Thierry André, Romain Cohen, Mohamed E. Salem · 2022 · American Society of Clinical Oncology Educational Book
23. Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine
    Nicolas D. Huyghe, Elena Benidovskaya, Philippe Stevens, Marc Van den Eynde · 2022 · Cancers
24. Prognostic and Predictive Molecular Biomarkers in Advanced Colorectal Cancer
    Valentino Martelli, Alessandro Pastorino, Alberto Felice Sobrero · 2022 · Pharmacology & Therapeutics
25. Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
    Javier Ros, Francesca Balconi, Iosune Baraibar, Nadia Saoudi Gonzalez, Francesc Salvà, Josep M. Tabernero, Elena Élez · 2023 · Frontiers in Oncology
26. Making Sense of Composite Endpoints in Clinical Research
    Daniela Baracaldo-Santamaría, John Edwin Feliciano-Alfonso, Raúl Ramírez Grueso, Luis Carlos Rojas-Rodríguez, Camilo Alberto Domínguez-Domínguez, Carlos‐Alberto Calderón‐Ospina · 2023 · Journal of Clinical Medicine
27. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study
    Michael James Overman, Fabio Gelsomino, Massimo Aglietta, Mark Ka Wong, María Luisa Limón Mirón, Gregory Leonard, Pilar García Alfonso, Andrew G Hill, Antonio Cubillo Gracián, Eric Van Cutsem et al. · 2024 · Journal for ImmunoTherapy of Cancer
28. Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
    Borelli, Beatrice, Antoniotti, Carlotta, Carullo, Martina, Germani, Marco Maria, Conca, Veronica, Masi, Gianluca · 2022 · Cancers
29. Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review
    Yusheng Guo, Dongqiao Xiang, Jiayu Wan, Lian Yang, Chuansheng Zheng · 2022 · Cancers
30. Illness trajectories of incurable solid cancers
    Eric C. T. Geijteman, Evelien J. M. Kuip, Jannie Oskam, Diana C. Lees, Eduardo D Bruera · 2024 · BMJ
31. Advances on colorectal cancer 3D models: The needed translational technology for nanomedicine screening
    Flávia Castro, Catarina Leite Pereira, Maria Helena Macedo, Andreia Almeida, Maria José Silveira, Sofia Dias, Ana Patrícia Cardoso, María José Oliveira, Bruno Filipe Carmelino Cardoso Sarmento · 2021 · Advanced Drug Delivery Reviews
32. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer
    Iosune Baraibar, Oriol Mirallas, Nadia Saoudi Gonzalez, Javier Ros, Francesc Salvà, Josep M. Tabernero, Elena Élez · 2021 · Cancers
33. Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications
    Cao, Qing, Tian, Ye, Deng, Zhiyi, Yang, Fangfang, Chen, Erfei · 2024 · International Journal of Molecular Sciences
34. Preclinical models as patients’ avatars for precision medicine in colorectal cancer: past and future challenges
    Erika Durinikova, Kristi Buzo, Sabrina Arena · 2021 · Journal of Experimental & Clinical Cancer Research
35. Tumour heterogeneity and evolutionary dynamics in colorectal cancer
    Dedrick Kok Hong Chan, Simon J. A. Buczacki · 2021 · Oncogenesis
36. How Do We Predict a Patient’s Disease Course and Whether They Will Respond to Specific Treatments?
    Bram Verstockt, Miles Parkes, James Christopher Lee · 2022 · Gastroenterology
37. DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion
    Baiwen Chen, Jiajia Hu, Xianting Hu, Huifang Chen, Rujuan Bao, Yatao Zhou, Youqiong Ye, Meixiao Zhan, Wei Cai, Huabin Li et al. · 2022 · Nature Communications
38. Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
    Erika Durinikova, Nicole Megan Reilly, Kristi Buzo, Elisa Mariella, Rosaria Chilà, Annalisa Lorenzato, João M.L. Dias, Gaia Grasso, Federica Pisati, Simona Lamba et al. · 2022 · Clinical Cancer Research
39. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
    Talal El Zarif, Amin H. Nassar, Gregory R. Pond, Tony Zhuang, Viraj A. Master, Bassel Nazha, Scot Anthony Niglio, Nicholas I. Simon, Andrew Warren Hahn, Curtis Alvin Pettaway et al. · 2023 · JNCI Journal of the National Cancer Institute
40. Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020
    Caixia Dong, Yuwei Ding, Shanshan Weng, Guichao Li, Yanqing Huang, Hanguang Hu, Zhen Zhang, Suzhan Zhang, Ying Yuan · 2021 · Chinese Journal of Cancer Research
41. Histopathological Growth Patterns and Survival After Resection of Colorectal Liver Metastasis: An External Validation Study
    Diederik J. Höppener, Boris Galjart, Pieter M. H. Nierop, Florian E. Buisman, Eric P. van der Stok, Robert R.J. Coebergh van den Braak, Martin J. van Amerongen, Vinod P. Balachandran, William R. Jarnagin, T. Peter Kingham et al. · 2021 · JNCI Cancer Spectrum
42. Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature
    Marissa Z. Guo, Ning Yi Jin, Timothy Michael Pawlik, Jordan M. Cloyd · 2021 · World Journal of Gastrointestinal Oncology
43. Current Developments of Artificial Intelligence in Digital Pathology and Its Future Clinical Applications in Gastrointestinal Cancers
    Alex Ngai Nick Wong, Zebang He, Ka Long Leung, Curtis Chun Kit To, Chun Yin Wong, Sze Chuen Cesar Wong, Jung Sun Yoo, Cheong Kin Ronald Chan, Angela Zaneta Chan, Maribel D. Lacambra et al. · 2022 · Cancers
44. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability
    Toky Ratovomanana, Rémy Nicolle, Romain Cohen, Adam Diehl, Aurélie Siret, Quentin Letourneur, Olivier Buhard, Alexandre Perrier, Erell Guillerm, Florence Coulet et al. · 2023 · Annals of Oncology
45. Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view
    Jakob Michael Riedl, Florian Moik, Tamara Esterl, Sarah M. Kostmann, Armin Gerger, Philipp Jakob Jost · 2023 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
46. Mitochondrial genome transfer drives metabolic reprogramming in adjacent colonic epithelial cells promoting TGFβ1-mediated tumor progression
    Bingjie Guan, Youdong Liu, Bowen Xie, Senlin Zhao, Abudushalamu Yalikun, W.T. Chen, Menghua Zhou, Qi Gu, Dongwang Yan · 2024 · Nature Communications
47. Informative censoring of surrogate end-point data in phase 3 oncology trials
    Shai Gilboa, Yarden Pras, Aviv Mataraso, David Bomze, Gal Markel, Tomer Meirson · 2021 · European Journal of Cancer
48. Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota
    Zishuo Ian Hu, Verena M. Link, Djalma Souza Lima-Junior, Jeremie Delaleu, Nicolas Jean Bouladoux, Seong‐Ji Han, Nicholas Collins, Yasmine Belkaid · 2022 · Proceedings of the National Academy of Sciences
49. Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
    Yuanling Tang, Dandan Li, Jia-Yu Duan, Leiming Sheng, Xin Wang · 2023 · World Journal of Gastroenterology
50. Radioimmunotherapy in colorectal cancer treatment: present and future
    Jingyi Shi, Zhuang Sun, Zhaoya Gao, Dandan Huang, Haopeng Hong, Jin Fa Gu · 2023 · Frontiers in Immunology
51. Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back
    Annapaola Mariniello, Maxime Borgeaud, MARC H. WEINER, Daniele Frisone, Floryane Kim, Alfredo Addeo · 2025 · BioDrugs
52. Precision medicine for metastatic colorectal cancer in clinical practice
    Julian E. Riedesser, Matthias P A Ebert, Johannes Betge · 2022 · Therapeutic Advances in Medical Oncology
53. Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies
    Yihan Wang, Kai Lu, Xu Yang, Shengshan Xu, Hongyu Chu, Xuedong Fang · 2025 · Frontiers in Immunology
54. How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies
    Richard Gallon, Peter Gawthorpe, Rachel Phelps, Christine M. Hayes, Gillian M. Borthwick, Mauro Santibanez‐Koref, Michael S. Jackson, John Burn · 2021 · Cancers
55. Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
    Elisa Grassi, Jody Corbelli, Giorgio Papiani, Maria Aurelia Barbera, Federica Gazzaneo, Stefano Tamberi · 2021 · Frontiers in Oncology
56. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
    Zhengyang Yang, Guocong Wu, Xiao Zhang, Jiale Gao, Cong Meng, Yishan Liu, Qi Wei, Liting Sun, Pengyu Wei, Zhigang Bai et al. · 2022 · Frontiers in Immunology
57. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal Cancer
    Oluwadunni Eunice Emiloju, Frank A. Sinicrope · 2023 · JAMA Oncology
58. Mitochondrial metabolic reprogramming in colorectal cancer: mechanisms of resistance and future clinical interventions
    Xiuxiu Qiu, Ao Wang, Jiahui Wang, Zhanxia Zhang, Li Tao · 2025 · Cell Death Discovery
59. TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
    Alessandra Raimondi, Federica Palermo, Michele Prisciandaro, Massimo Aglietta, Lorenzo Antonuzzo, Giuseppe Aprile, Rossana Berardi, Giovanni Gerardo Cardellino, Giovanni De Manzoni, Ferdinando De Vita et al. · 2021 · Cancers
60. Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer
    Chang Woo Kim, Hong Jae Chon, Chan Kim · 2021 · Cancers
61. Microsatellite Instability and Metastatic Colorectal Cancer – A Clinical Perspective
    Tomáš Büchler · 2022 · Frontiers in Oncology
62. Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
    Bahar Saberzadeh-Ardestani, Jeremy Clifton Jones, Joleen Marie Hubbard, Robert R. McWilliams, Thorvardur Ragnar Halfdanarson, Qian Shi, Mohamad Bassam Sonbol, Jonathan Ticku, Zhaohui Jin, Frank A. Sinicrope · 2023 · JAMA Network Open
63. Management of immune-related cutaneous adverse events with dupilumab
    Alyce Mei-Shiuan Kuo, Stephanie Gu, Joseph R. Stoll, Andrea Primiani Moy, Stephen W. Dusza, Allison Gordon, Elena C. Haliasos, Yelena Yuriy Janjigian, Lukas Kraehenbuehl, Elizabeth A. Quigley et al. · 2023 · Journal for ImmunoTherapy of Cancer
64. Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer
    Mehmet Akce, Batoul Farran, Jeffrey M. Switchenko, Manali Rupji, Sandra Kang, Lana E. Khalil, Amanda N. Ruggieri, Brian M. Olson, Walid Labib Shaib, Christina Sing-Ying Wu et al. · 2023 · Journal for ImmunoTherapy of Cancer
65. Helicobacter pylori and immunotherapy for gastrointestinal cancer
    Keren Jia, Yang Chen, Yi Xie, Xicheng Wang, Yajie Hu, Yu Sun, Yanshuo Cao, Liyan Zhang, Yakun Wang, Zhenghang Wang et al. · 2024 · The Innovation
66. The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies
    Qingzhe Wang, Min Yu, Shuang Zhang · 2025 · Frontiers in Immunology
67. Functional and Therapeutic Significance of Tumor-Associated Macrophages in Colorectal Cancer
    Yitong Li, Zhenmei Chen, Jiahao Han, Xiaochen Ma, Xin Zheng, Jinhong Chen · 2022 · Frontiers in Oncology
68. Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
    Anwaar Saeed, Robin Park, Harsh B. Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind A. Phadnis, Raed Moh’d Taiseer Al-Rajabi, Anup Kasi, Joaquina Celebre Baranda, Weijing Sun et al. · 2024 · Nature Communications
69. EZH2 Inhibition Enhances PD‐L1 Protein Stability Through USP22‐Mediated Deubiquitination in Colorectal Cancer
    Jiaqi Huang, Qianqian Yin, Yuqing Wang, Xin Zhou, Yunyun Guo, Yuanjun Tang, Rui Cheng, Xiaotong Yu, Jie Zhang, Chen Lung Huang et al. · 2024 · Advanced Science
70. Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets
    Alberto Puccini, Kelsey Anne Poorman, Fabio Catalano, Andreas Seeber, Richard M. Goldberg, Mohamed E. Salem, Anthony Frank Shields, Martin D. Berger, Francesca Battaglin, Ryuma Tokunaga et al. · 2022 · Oncogene
71. Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival
    Qiutong Huang, Nicolas Jacquelot, Adele Preaudet, Soroor Hediyeh-zadeh, Fernando Souza-Fonseca-Guimarães, Andrew N. J. McKenzie, Philip M. Hansbro, Melissa J. Davis, Lisa Anna Mielke, Tracy L. Putoczki et al. · 2021 · Cancers
72. Immunosenescence, inflammaging, and cancer immunotherapy efficacy
    Julieta E. Rodriguez, Marie Naigeon, Vincent Goldschmidt, Matthieu Roulleaux Dugage, Lauren Seknazi, François‐Xavier Danlos, Stéphane Champiat, Aurélien Marabelle, Jean‐Marie Michot, Christophe Massard et al. · 2022 · Expert Review of Anticancer Therapy
73. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Benny Johnson, Cara Haymaker, Edwin Roger Parra, Luisa M. Solis Soto, Xuemei Wang, Jane Varkey Thomas, Arvind N. Dasari, Van Karlyle Morris, Kanwal P. S. Raghav, Eduardo Vilar et al. · 2022 · Journal for ImmunoTherapy of Cancer
74. Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability
    Tao Wu, Xuan Zhang, Xinxing Liu, Xinyi Cai, Tao Shen, Dingguo Pan, Rui Liang, Rong Ding, Ruixi Hu, Jianhua Dong et al. · 2023 · BMC Medicine
75. Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The Ongoing Search for Biomarkers
    Javier Ros, Iosune Baraibar, Nadia Saoudi Gonzalez, Marta Rodríguez-Castells, Francesc Salvà, Josep M. Tabernero, Elena Élez · 2023 · Cancers
76. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer
    Jörg Trojan, Sebastian Stintzing, Oliver Haase, Christine Koch, Paul K. Ziegler, Melanie C Demes, Ivan Jelas · 2021 · The Oncologist
77. BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues
    İbrahim Halil Şahin, Jim Klostergaard · 2021 · JCO Oncology Practice
78. Precision Oncology: a Clinical and Patient Perspective
    Ulrik Lassen, Lydia Makaroff, Albrecht Stenzinger, Antoîne Italiano, Gilles Vassal, Jesús García‐Foncillas, Bernard P. Avouac · 2021 · Future Oncology
79. Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
    Valentina Russo, Eleonora Lallo, Armelle Munnia, Miriana Spedicato, Luca Messerini, Romina D’Aurizio, Elia Giuseppe Ceroni, Giulia Brunelli, Antonio Galvano, Antonio Russo et al. · 2022 · Cancers
80. Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis
    Yuegang Li, Yuwei Du, Chi Xue, Pei Wu, Nan Du, Guolian Zhu, Huimian Xu, Zhu Zhi · 2022 · BMC Gastroenterology
81. Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy
    Valsamo Anagnostou, Blair V. Landon, Jamie E. Medina, Patrick M. Forde, Victor E. Velculescu · 2022 · Science Translational Medicine
82. Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation
    Yaqi Wang, Lijun Shen, Juefeng Wan, Hui Zhang, Ruiyan Wu, Jingwen Wang, Yan Wang, Ye Xu, Sanjun Cai, Zhen Zhang et al. · 2022 · Frontiers in Immunology
83. Immunotherapy of MSI Cancer: Facts and Hopes
    Helen Catherine Wilbur, Dung Thi Le, Parul Agarwal · 2023 · Clinical Cancer Research
84. Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment
    Junge Bai, Hongsheng Chen, Xuefeng Bai · 2021 · Journal of Clinical Laboratory Analysis
85. Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease
    Elizabeth Ann Mittendorf, Femke H. Burgers, John B.A.G. Haanen, Tina Cascone · 2022 · American Society of Clinical Oncology Educational Book
86. Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation
    Ray Sagawa, Seiji Sakata, Bo Gong, Yosuke Seto, Ai Takemoto, Satoshi Takagi, Hironori Ninomiya, Noriko Yanagitani, Masayuki Nakao, Mingyon Mun et al. · 2021 · JCI Insight
87. Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer
    Qingli Li, Xiaojiao Cheng, Cong Zhou, Yaoliang Tang, Fuli Li, Baiwen Zhang, Tinglei Huang, Jianzheng Wang, Shuiping Tu · 2022 · Frontiers in Oncology
88. Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers
    Marta Chiaravalli, Alexia Spring, Antonio Agostini, Geny Piro, Carmine Carbone, Giampaolo Tortora · 2022 · Cells
89. scRNA-seq of colorectal cancer shows regional immune atlas with the function of CD20+ B cells
    Linlin Ji, Gongbo Fu, Mengxi Huang, Xiaoming Kao, Jialong Zhu, Zhe Dai, Yitian Chen, Huiyu Li, Jie Zhou, Xiaoyuan Chu et al. · 2024 · Cancer Letters
90. Ageing, immune fitness and cancer
    Melissa Dolan, Kendra A. Libby, Alison Epstein Ringel, Peter van Galen, Sandra S. McAllister · 2025 · Nature reviews. Cancer
91. FRESCO-2: A Global Phase III Study Investigating the Efficacy and Safety of Fruquintinib in Metastatic Colorectal Cancer
    Arvind N. Dasari, Alberto Felice Sobrero, James C. Yao, Takayuki Yoshino, William R. Schelman, Zhao Yang, Caly Chien, Marek K. Kania, Josep M. Tabernero, Cathy Eng · 2021 · Future Oncology
92. Deep learning for the detection of microsatellite instability from histology images in colorectal cancer: A systematic literature review
    Amelie Echle, Narmin Ghaffari Laleh, Peter L. Schrammen, Nicholas Paul West, Christian Trautwein, Titus J. Brinker, Stephen B. Gruber, Roman David Bülow, Peter Boor, Heike Irmgard Grabsch et al. · 2021 · ImmunoInformatics
93. Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH)
    Yaqi Wang, Lijun Shen, Juefeng Wan, Hui Zhang, Ruiyan Wu, Jingwen Wang, Yan Wang, Ye Xu, Sanjun Cai, Zhen Zhang et al. · 2022 · BMC Cancer
94. Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer
    Pashtoon Murtaza Kasi, Griffin L. Budde, Michael R. Krainock, Vasily N. Aushev, Allyson Koyen Malashevich, Meenakshi Malhotra, Perry Olshan, Paul R. Billings, Alexey A. Aleshin · 2022 · Journal for ImmunoTherapy of Cancer
95. Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally
    Yochai Wolf, Yardena Samuels · 2022 · Clinical Cancer Research
96. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas
    Pier Selenica, Antonio Marra, Noura J. Choudhury, Andrea M. Gazzo, Christina J. Falcon, Juber Patel, Xin Pei, Yingjie Zhu, Charlotte K.Y. Ng, Michael Curry et al. · 2022 · Annals of Oncology
97. Mechanisms of colorectal liver metastasis development
    Tal Shasha, Mandy Gruijs, Marjolein van Egmond · 2022 · Cellular and Molecular Life Sciences
98. Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors
    Yumo Xie, Jinxin Lin, Ning Zhang, Xiaolin Wang, Puning Wang, Shaoyong Peng, Juan Li, Yuanhui Wu, Yaoyi Huang, Zhuokai Zhuang et al. · 2023 · Journal of the National Comprehensive Cancer Network
99. Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy
    Alexandra Kavun, Egor Veselovsky, Alexandra Lebedeva, Ekaterina Belova, Olesya A. Kuznetsova, Valentina D. Yakushina, Tatiana V. Grigoreva, Vladislav Mileyko, Mikhail Yu. Fedyanin, Maxim V. Ivanov · 2023 · Cancers
100. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials
     Julien Taı̈eb, Frank A. Sinicrope, Levi Pederson, Sara Lonardi, Steven R. Alberts, Thomas J. George, Greg Yothers, Eric Van Cutsem, Leonard B. Saltz, Shuji Ogino et al. · 2023 · Annals of Oncology